Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.

Document Type

Journal Article

Publication Date

9-1-2015

Journal

Journal of Immunotherapy

Volume

38

Issue

7

Inclusive Pages

299-305

DOI

10.1097/CJI.0000000000000088

Keywords

Antigens, CD19--immunology; Antineoplastic Agents--therapeutic use; B-Lymphocytes--immunology; Immunotoxins--immunology; Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma--immunology; Ribosome Inactivating Proteins, Type 1--immunology

Comments

PMCID: PMC4536569 [Available on 2016-09-01]

Peer Reviewed

1

Share

COinS